No Data
No Data
Neutral Hold Rating on Cogent Biosciences With a $8 Price Target Amidst Clinical and Market Evaluation
We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
Express News | HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $19 Price Target
Buy Rating on Cogent Biosciences: Financial Stability and Promising Clinical Trials Fuel Positive Outlook
Analyst Issues Buy Rating on Cogent Biosciences Amid Clinical and Financial Milestones
Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)